genOway | ULTIMATE PREDICTABILITY

genO-hPD-1 (scan or click)

HUMANIZED genO-hPD-1 MOUSE MODEL

The genO-hPD-1 mouse enables the *in vivo* efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice


APPLICATIONS

genO-hPD-1 drives advances across **immuno-oncology**, **immuno-inflammation**, and **autoimmunity**, enabling the following applications:

- ☑ Assess the **efficacy** of PD-1-targeting compounds
  - Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
  - Evaluate PD-1 agonists for the treatment of autoimmune and inflammatory conditions
- ☑ Gain insights into the **mechanism of action** (MOA) of diverse constructs and their potential therapeutic benefits

MODEL USED BY

abbvie · ANAVEON · AstraZeneca · BONUM · Bristol Myers Squibb · charles river · ChemoCentryx · CIDARA THERAPEUTICS · janssen · REACTION BIOLOGY · SEISMIC THERAPEUTIC



MODEL FEATURES

- ☑ Physiological regulation and expression of humanized PD-1
- ☑ Lack of expression of the murine target gene
- ☑ Fully functional mouse immune system
- ☑ Available on different genetic backgrounds C57BL/6 & BALB/c

INDS WITH THE MODEL

Bristol Myers Squibb — **Opdivo® (nivolumab)**, the first approved immunotherapy, was tested in a **custom genOway model** that served as the foundation for **genO-hPD-1**

ANAVEON — **Molecule tested: ANV600**

SEISMIC THERAPEUTIC — **Molecule tested: S-4321**

ORDERS, DELIVERY & CARE

- ☑ Orders are made directly with genOway; breeding, housing and delivery are outsourced
- ☑ Breeding facilities in the US and Europe through our trusted partners:

TACONIC BIOSCIENCES · charles river


- ☑ Quick, compliant, and reliable door-to-door delivery worldwide at your facility or at the CRO of your choice
- ☑ Models with certified **SOPF** health status from **AAALAC-accredited** and **PHS-assured** professional breeders

genOway | ULTIMATE PREDICTABILITY


genO-hPD-1 (scan or click)

SELECTED VALIDATION DATA

More data available on our website or upon request



hPD-1 expression pattern and modulation upon activation recapitulates mPD-1



In vivo anti-tumor activity is observed in response to a PD-1-targeted IL-2Rβγ agonist (ANV600) in genO-hPD-1 mice

ANVEON

KEY PUBLICATIONS

ANVEON

ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy
Murer et al., 2025 - Journal for ImmunoTherapy of Cancer

abbvie

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
Chan et al., 2022 - Nature Cancer

janssen

Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells
Helou et al., 2022 - Journal of Allergy and Clinical Immunology

LISBOA | UNIVERSIDADE DE LISBOA

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
Acúrcio et al., 2022 - Journal for ImmunoTherapy of Cancer

RELATED MODELS

MICE		CELLS	
genO-hPD-1/hCTLA-4	genO-hPD-1/hGITR/hGITRL	genO-MC38-hPD-L1-hCD47-LZ	genO-MC38-hPD-L1-LZ
genO-hPD-1/hICOS	genO-hPD-1/hLAG3	genO-MC38-hPD-L1-hHER2-LZ	genO-CT26-hPD-L1
genO-hPD-1/hTIM3	genO-hPD-1/hPD-L1	genO-MC38-Pd-l1KO	genO-CT26-Pd-l1KO
genO-panhCD3/hPD-1	genO-hPD-1/hVISTA	genO-MC38-hPD-L1-hFAP-LZ	

For more information

Visit the genO-hPD-1 page

For further inquiries

Contact Us